Makerere University

mak.ac.ug

Total trials

141

Active

13

Phase 3

25

Total enrollment

235,779

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 6 of 6 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Single dose liposomal Amphotericin and Fluconazole1
Fluconazole1
Doxycycline2
CAd31
ChAdox11
rVSV-SUDV1

Next readouts

  • 2026-12-20
  • 2027-06
  • 2027-09

Top conditions

  • HIV11
  • HIV Infections10
  • Malaria8
  • HIV/AIDS6
  • Tuberculosis6
  • Covid193
  • HIV-1-infection3
  • PrEP3

Frequently asked questions about Makerere University

How many clinical trials does Makerere University have on ClinicalTrials.gov?
Makerere University is listed as the lead sponsor on 141 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
How many of Makerere University's trials are in Phase 3?
25 of Makerere University's trials are in Phase 3, spread across 6 active drug programs.
What therapeutic areas does Makerere University focus on?
Makerere University's most-studied conditions on ClinicalTrials.gov are HIV, HIV Infections, Malaria, HIV/AIDS, Tuberculosis.
When are Makerere University's next clinical trial readouts?
Makerere University has 3 upcoming primary-completion readouts tracked here; the soonest is “Characterization of Tuberculosis Associated Lung Fibrosis and Respiratory Impairment, and Prevention Using Doxycycline”, expected around 2026-12-20.